Xigduo 5 mg/850 mg & 5 mg/1,000 mg film coated tablets
Last Updated on eMC 12-Jun-2017 View document | AstraZeneca UK Limited Contact details
When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.
Updated on 12-Jun-2017 and displayed until Current
Reasons for adding or updating:
- Correction of spelling/typing errors
Updated on 02-May-2017 and displayed until 12-Jun-2017
Reasons for adding or updating:
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
- Improved presentation of PIL
Updated on 23-Dec-2016 and displayed until 02-May-2017
Reasons for adding or updating:
- Change to section 2 - what you need to know - contraindications
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 16-May-2016 and displayed until 23-Dec-2016
Reasons for adding or updating:
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
- Change to section 4 - how to report a side effect
- Change to section 6 - date of revision
Updated on 08-Jan-2015 and displayed until 16-May-2016
Reasons for adding or updating:
- Change to section 6 - what the product looks like and pack contents
- Change to section 6 - manufacturer
- Change to section 6 - date of revision
Updated on 15-Oct-2014 and displayed until 08-Jan-2015
Reasons for adding or updating:
- Change to section 6 - marketing authorisation holder
- Change to section 6 - date of revision
Updated on 07-Aug-2014 and displayed until 15-Oct-2014
Reasons for adding or updating:
- Change to section 4 - possible side effects
- Change to section 4 - how to report a side effect
- Change to section 6 - date of revision
Updated on 01-May-2014 and displayed until 07-Aug-2014
Reasons for adding or updating:
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 2 - driving and using machines
- Change to section 3 - how to take/use
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 27-Feb-2014 and displayed until 01-May-2014
Reasons for adding or updating:
- New PIL for new product
AstraZeneca UK Limited
Horizon Place, 600 Capability Green, Luton, Bedfordshire, LU1 3LU
+44 (0)1582 838 000
+44 (0)1582 838 003
+44 (0)1582 836 000
0800 783 0033
+44 (0)1582 837 837
Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Active ingredients
Legal categories
This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue